质子再照射治疗局部区域复发性乳腺癌
单机构回顾性研究纳入27例既往接受光子放疗后局部区域复发的乳腺癌患者,采用质子再照射,中位剂量51 Gy,最常见分次为1.5 Gy每日两次。中位随访16.6个月,急性3级毒性为皮炎和乳腺疼痛各2例,≥2级晚期毒性包括6例2级肋骨骨折等;局部区域控制率>95%,12例出现新复发,7例死亡。
要点
- 质子再照射中位剂量51 Gy(1.5 Gy每日两次)用于乳腺癌局部区域复发。
- 急性3级毒性为皮炎和乳腺疼痛各2例;≥2级晚期毒性以2级肋骨骨折最常见(6例)。
- 局部区域控制率>95%,但仍有12例新发复发和7例死亡。
核心结论
- 质子挽救性再照射中位51 Gy(1.5 Gy每日两次)安全可耐受,急性及晚期毒性可接受,局部区域控制率>95%。
研究设计与样本
- 单机构回顾性研究,纳入2012至2019年27例既往同区域光子放疗后局部区域复发且接受质子再照射的乳腺癌患者。
主要发现
- 再照射中位剂量51 Gy,最常见分次为1.5 Gy每日两次;两次放疗中位间隔9.7年。
- 急性3级毒性为皮炎2例、乳腺疼痛2例;≥2级晚期毒性包括6例2级肋骨骨折、1例2级臂丛神经病、1例3级皮炎、1例3级乳腺疼痛、1例4级皮炎。
- 中位随访16.6个月,12例出现新发复发(其中1例为野内第二局部区域复发),7例死亡。
关键数值与推荐
- 质子再照射方案包括全乳/胸壁加区域淋巴结放疗22/27、单纯淋巴结放疗2/27、单纯全乳/胸壁放疗3/27。
临床怎么用
- 对于既往接受过光子放疗的乳腺癌局部区域复发患者,质子再照射可作为挽救性治疗选择,需关注肋骨骨折等晚期毒性。
局限性
- 单机构回顾性研究,样本量27例,随访时间较短(中位16.6个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Local-regional recurrence (LRR) of breast cancer after prior adjuvant radiation (RT) can present a clinical challenge. Proton therapy is recommended by the American Society for Radiation Oncology in cases where reirrradiation is needed; however, data are limited. We present the toxicity and outcomes after reirradiation for local-regional recurrence of breast cancer with proton therapy. METHODS AND MATERIALS: A single-institution retrospective review identified patients with the following criteria: LRR of breast cancer, prior photon radiation to the same region, proton beam reirradiation, and definitive intent. Surgery or systemic therapy at the time of recurrence was used when indicated. The log-rank test was used to compare Kaplan-Meier survival estimates. Kruskal-Wallis tests were performed to compare worst reported toxicities with clinical variables. RESULTS: The population included 27 patients with a history of prior radiation and treated with proton therapy for LRR between 2012 and 2019. The median interval between courses was 9.7 years. Proton reirradiation regimens included whole breast/chest wall (WB/CW) with regional nodal RT (22/27), nodal RT alone (2/27), or WB/CW alone (3/27). The median dose was 51 Gy, and the most common fractionation was 1.5 Gy twice daily. Median follow-up after reirradiation was 16.6 months. Acute grade 3 toxicities included dermatitis in 2 patients and breast pain in 2 patients. Grade 2 or higher late toxicities included 6 G2 rib fractures and 1 G2 brachial plexopathy, 1 G3 dermatitis, 1 G3 breast pain, and 1 G4 dermatitis. Twelve patients had new documented recurrences of which 1 was a second in-field LRR, and there were 7 deaths. CONCLUSIONS: Proton salvage reirradiation to median 51 Gy in 1.5 Gy twice daily appears to be safe with acceptable acute and late toxicity, and effective with >95% local-regional control.
引用
- LaRiviere MJ, Dreyfuss A, Taunk NK, et al. Proton Reirradiation for Locoregionally Recurrent Breast Cancer. Adv Radiat Oncol. 2021. PMID: 34409209. doi:10.1016/j.adro.2021.100710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。